Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia
Authors: Tatsuya Ohno
Masaru Wakatsuki
Dang Huy Quoc Thinh
Ngo Thanh Tung
Dyah Erawati
Nana Supriana
C. R. Beena Devi
Shingo Kato
Kullathorn Thephamongkhol
Yaowalak Chansilpa
Miriam Joy C. Calaguas
Xu Xiaoting
Cao Jianping
Parvin Akhter Banu
Chul Koo Cho
Kumiko Karasawa
Takashi Nakano
Hirohiko Tsujii
Gunma University
National Institute of Radiological Sciences Chiba
Biotechnology Center of Ho Chi Minh City
National Cancer Hospital
Dr. Soetomo Hospital
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Sarawak General Hospital
Saitama Medical University
Mahidol University
St. Luke's Medical Center Quezon City
Soochow University
Delta Hospitals Limited
Korea Institute of Radiological and Medical Sciences
Gunma University Faculty of Medicine
Keywords: Environmental Science
Issue Date: 1-Jan-2016
Citation: Journal of Radiation Research. Vol.57, No.1 (2016), 44-49
Abstract: © 2015 The Author 2015. The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3-4 and N0-1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3-4 N0-1 M0, World Health Organization Type 2-3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m2). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3-4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis-free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.
ISSN: 13499157
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.